The clinical and microbiological characteristics of 103 patients with cultures positive for non-Aspergillus moulds in the period 2000 to 2008 were described. Among these patients, 27 had proven or probable invasive infections caused by Fusarium (n = 12), Paecilomyces (n = 7), Zygomycetes (n = 5) and Scedopsorium species (n = 3). The incidence of invasive infections caused by these moulds has not increased during the study period. Lung was the most common infection site and disseminated disease was observed in three leukaemic patients. The overall mortality rate was 40.7%, and was highest in cases zygomycosis.
Invasive mould infections (IMIs) have emerged as a significant cause of infectious mortality in immunocompromised patients [1] . Although invasive aspergillosis (IA) represents the most common opportunistic mould infection, less commonly encountered moulds, such as Zygomycetes, Fusarium, Paecilomyces and Scedosporium species, have increasingly been reported to cause IMIs [2] [3] [4] [5] . Moreover, infections caused by these organisms are associated with a substantially worse outcome than IA [1] , which is most likely attributed both to the significant immunodeficient state of these patients and the innate resistance of these organisms to antifungal agents [4, [6] [7] [8] .
Because of the rarity of non-Aspergillus invasive infections, there is limited literature on the clinical characteristics of these mycoses [1, 5, 9] . Furthermore, reports on the drug susceptibility of these organisms are scarce [6] [7] [8] 10] .
In the present study, patients with cultures positive for Fusarium, Zygomycetes, Paecilomyces and Scedosporium species in the period 2000 to 2008 at the National Taiwan University Hospital were identified. Invasive mould infections were defined in accordance with the EORTC/MSG criteria [11] . The use of steroids was defined as usage within 30 days prior to obtaining the positive culture. Infection with the involvement of two or more noncontiguous organ sites was considered as disseminated disease. The outcome of the patients was defined as their status at 12 weeks after diagnosis. The isolates were identified to the species level by sequence comparison analysis of the internal transcribed spacer (ITS) regions using primers ITS1 and ITS4 as previously described [12] . For Fusarium species, sequence analysis of the translation elongation factor 1 alpha (EF1a) region was also performed with primers EF1 and EF2 [13] . MICs were determined by the broth microdilution method [14] .
Among the 141 positive cultures obtained from 103 patients, 27 cases (26.2%) met the criteria for proven or probable IMI. The aetiologic pathogens were Fusarium species in 12 (44.4%) patients, Paecilomyces species in seven (25.9%), Zygomycetes in five (18.5%) and Scedopsorium species in three (11.1%) ( Table 1 ). The annual incidence of IMIs caused by these ranged from 0.04 per 1000 admissions in 2006 to 0.31 per 1000 admissions in 2000, and was 0.17 per 1000 admissions in both 2007 and 2008. The reason we did not observe a similar trend of increased incidence of infections, as has been reported previously [3] [4] [5] , remains unknown. The limited use of broad-spectrum antifungal agents for prophylaxis in the hospital might partly explain this phenomenon [3] [4] [5] 15] .
Predisposing factors were identified in 25 of the 27 patients and included haematological malignancies (48%), steroid use (10.40%), solid organ tumor (3.12%), haematopoietic stem cell (1.4%) or solid organ transplantation (12%), AIDS (2.8%), diabetes mellitus (2.8%) and myelodysplastic syndrome (1.4%). The lung was the most common main infection site (33%), followed by orbito-sinus-facial (18.5%), skin and soft tissue (18.5%), blood (11.1%) and bile (7.4%). Disseminated disease was observed in three leukaemic patients who all presented with skin involvement.
A total of 21 patients received antifungal therapy and six patients received surgical treatment. Overall, amphotericin B (including liposomal amphotericin B) was the most frequently administered agent (81.0%), followed by fluconazole (52.4%), voriconazole (33.3%), itraconazole (23.8%) and caspofungin (9.5%).
Mortality at 12 weeks for all patients was 40.7%, and 76.9% for patients with haematological malignancies. Mortality was highest in patients with zygomycosis (four out of five patients died; 80%), despite all five patients in this group receiving antifungal therapy and three patients undergoing surgical treatment. All four patients who died had acute leukaemia, and one of them was an allogenic haematopoietic stem cell transplantat recipient. Patients with fusariosis were associated with the second highest mortality rate (41.7%), and all those who died had underlying haematological disorders.
Fifty-eight clinical isolates were available for ITS sequence analysis. The identified organisms include 29 Fusarium, 18 Paecilomyces, seven Zygomycetes and four Scedosporium species. Among the isolates, 41 reported only to the genus level by conventional methods were further identified to the species level. Of note, six isolates initially reported as Paecilomyces species by conventional methods were found to be Penicillium species (three isolates), Aspergillus versicolor (one isolate), different species of Paecilomyces (one isolate) and mixed Paecilomyces and Penicillium infection (one isolate) by sequence analysis. It has been reported that Paecilomyces and Penicillium species are often misidentified as a result of their similar reproductive structures [15] .
The geometric means and ranges of the MICs for eight antifungal agents are summarized in Table 2 . Fusarium species MDS, meylodysplastic syndrome; HSCT, haematopoietic stem cell transplant. a Six patients received surgical treatment, including lung decortication (n = 2), maxillectomy with eye extenteration (n = 1), eye evisceration (n = 1), arthroscopic surgery (n = 1) and functional sinus surgery (n = 1). exhibited high MICs for azoles and echinocandins, whereas 100% of the isolates were inhibited by £2 mg/L of amphotericin B. Paecilomyces isolates showed different susceptibility patterns among species. Several drugs demonstrated good in vitro activity against Paecilomyces variotii, whereas Paecilomyces lilacinus isolates had high MICs for most agents except for voriconazole and posaconazole. The susceptibility patterns of the rare species Paecilomyces spectabilis and Paecilomyces sinensis were similar to that of P. variotii. For the Zygomycetes, amphotericin B was the most active agent. Finally, Scedosporium apiospermum was relatively susceptible to the newer azoles, whereas S. prolificans had high MICs for all antifungal agents tested. Although Zygomycetes were the most commonly identified non-Aspergillus moulds recorded in other reports [1, 3] , Fusarium species comprised the rare moulds that were most frequently isolated in the present study. In addition, although Fusarium oxysporum and Fusarium moniliforme were found by multiple studies to be the most frequently isolated species after Fusarium solani [3, 6] , we did not identify either of these two species by sequence analysis. Instead, two isolates of Fusarium equisetii were detected. Furthermore, Paecilomyces infections constituted a significant proportion of IMIs in the present study (25.9%). The unique species distribution observed in the present study could be due to geography because most of the previous studies were conducted in Europe and North America [1] [2] [3] [4] [5] .
In conclusion, non-Aspergillus IMIs occurred predominantly in immunocompromised patients. Patients with underlying haematological disorders were associated with an increased risk of disseminated disease and high mortality. Antifungal susceptibility varied considerably among these species. This emphasizes the importance of identifying infecting moulds to the species level, which is seldom achieved in standard clinical laboratories.
